KEYTRUDA® (pembrolizumab) gets FDA approval for patients with recurrent or metastatic head and neck

Article link

The trend of checkpoint inhibitor approval in cancers with high mutational load continues. But that makes sense, given that this was the rationale for targeting those tumors first. This accelerated approval was based on response rate, so a confirmatory study is in the works